VIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life Study

VIGIP-SEP2: Evaluation of the Impact of the Training of Patients by a Nurse on the Adverse Drug Reaction Reporting by RRMS Patient Via a Mobile Application: Randomized Real-life Study

Publication date: Oct 04, 2019

The patient’s reporting of adverse drug reactions (ADRs) is recognized as being of interest for post-marketing safety monitoring, but is still underdeveloped in France, with an average lower than the European average. A multidisciplinary team of the University Hospital of Caen, composed of neurologists and pharmacovigilants, has been carrying out since autumn 2017 a national study (VIGIP-SEP1) with 24 research centers in France (12 universitary hospitals, 6 general hospitals, and 6 private-practice neurologists) whose main objective was to evaluate the impact of multiple sclerosis (MS) patients’ use of a mobile application (App) to report their ADRs. My eReport France(R) has been developed by the eVedrug company: ADR reports are sent by patients directly to the Regional Pharmacovigilance Centers, after analyze, clinical pharmacologist send it to the National Competent Authority. As part of VIGIP-SEP1, the accompaniment for the use of the App was carried out very simply by neurologists. We designed a randomized controlled trial based on the assumption that a nurse training of the patient, after the initial prescription of an oral MS drug, with a telephone follow-up within 6 months, will increase by 3 times the number of patients who report ADRs compared to a simple information presented by the neurologist. The number of subjects required is 23 subjects per group.

Concepts Keywords
ADR Multiple sclerosis
ADRs Neurology
Adverse Drug Reactions Pharmacovigilance
Caen Adverse drug reaction
Clinical Pharmacologist Pharmaceuticals policy
DMT Drug safety
France Clinical research
Informed Consent Clinical pharmacology
Mobile Healthcare quality
Multiple Sclerosis Articles
Neurologist Health
Pharmacovigilance
Randomized Controlled Trial
Telephone

Semantics

Type Source Name
gene UNIPROT ALG3
gene UNIPROT NR4A2
gene UNIPROT DMTN
drug DRUGBANK Dimethyltryptamine
gene UNIPROT LITAF
gene UNIPROT APP
disease DOID multiple sclerosis
disease MESH multiple sclerosis
gene UNIPROT XRN1
gene UNIPROT SLC35G1
gene UNIPROT DESI1
disease DOID RRMS
disease MESH Adverse Drug Reaction
gene UNIPROT IMPACT
gene UNIPROT SEPTIN6

Similar

Original Article

Leave a Comment

Your email address will not be published. Required fields are marked *